AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors on 2 June 2014, as compelling data from over 40 scientific abstracts related to AstraZeneca and MedImmune investigational medicines were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

AstraZeneca today announced that the US Food and Drug Administration (FDA) has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product (QIDP) and awarded its development programme Fast Track status for the treatment of uncomplicated gonorrhoea, which is increasingly resistant to existing antibiotics and poses a serious global public health threat.

As part of the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), Dr Joyce Liu today presented data on a Phase II study conducted by the American National Cancer Institute (NCI), comparing the efficacy and tolerability of olaparib and cediranib in combination to olaparib alone, for the treatment of women with recurrent platinum-sensitive high-grade serous ovarian cancer (abstract LBA5500). This is the first ovarian cancer study to use a combination of investigational medicines that can be taken orally.

A copy of this statement is available on our website.

AstraZeneca PLC (“AstraZeneca”) notes the announcement made by Pfizer Inc. (“Pfizer”) dated 19 May 2014 seeking to clarify certain matters set out in its announcement on 18 May 2014 which set out its final proposal to AstraZeneca (the “Final Proposal Announcement”).

A copy of this statement is available on our website.

AstraZeneca today announced its intention to collaborate with the Medical Research Council Laboratory of Molecular Biology (MRC LMB) to fund a range of pre-clinical research projects aimed at better understanding the biology of disease.

This week AstraZeneca demonstrated further evidence of continued progress of its science-led strategy, as the company updated on new data in advance of key medical and scientific congresses across all of its core therapeutic areas – oncology, cardiovascular and metabolic disease and respiratory, inflammation and autoimmunity.

New data from AstraZeneca’s investigational cancer medicines demonstrate the rapid progression of its oncology pipeline. Over 40 scientific abstracts from AstraZeneca and its global biologics R&D arm MedImmune will be featured at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) at the end of this month.